We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

45 hedge funds and large institutions have $222M invested in Y-mAbs Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

27% more capital invested

Capital invested by funds: $176M → $222M (+$46.6M)

7% more funds holding

Funds holding: 42 → 45 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.6% less ownership

Funds ownership: 25.41% → 24.8% (-0.6%)

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

Holders
45
Holders Change
+3
Holders Change %
+7.14%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
13
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$11.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.51M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$2.36M
4
BlackRock
BlackRock
New York
+$600K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$599K

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$14.7M
2
ACA
Avoro Capital Advisors
New York
-$6.3M
3
Millennium Management
Millennium Management
New York
-$2.23M
4
AG
Artal Group
Luxembourg
-$1.02M
5
MWNA
Marshall Wace North America
New York
-$844K
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
26
Tiverton Asset Management
Delaware
$219K – – –
AIG
27
American International Group
New York
$116K -$3.16K -144 -3%
FCM
28
Flinton Capital Management
Pennsylvania
$110K – – –
Wells Fargo
29
Wells Fargo
California
$96K +$1.69K +77 +2%
TAM
30
Tyers Asset Management
Texas
$90K – – –
NA
31
Neuburgh Advisers
California
$71K – – –
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$63K +$52.7K +2,400 New
MCIM
33
Meadow Creek Investment Management
Georgia
$52K – – –
SO
34
STRS Ohio
Ohio
$49K – – –
Citigroup
35
Citigroup
New York
$49K +$549 +25 +1%
UBS Group
36
UBS Group
Switzerland
$39K -$48.3K -2,201 -60%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$37.9K +$31.8K +1,447 New
Morgan Stanley
38
Morgan Stanley
New York
$37K -$210K -9,584 -87%
Legal & General Group
39
Legal & General Group
United Kingdom
$28K – – –
MWNA
40
Marshall Wace North America
New York
$19K -$844K -38,448 -98%
AIP
41
Ameritas Investment Partners
Nebraska
$15K – – –
CCA
42
Catalyst Capital Advisors
New York
$10K -$2.2K -100 -20%
TRCT
43
Tower Research Capital (TRC)
New York
$6K -$3.12K -142 -40%
Rockefeller Capital Management
44
Rockefeller Capital Management
New York
$4K +$3.29K +150 New
ACA
45
Avoro Capital Advisors
New York
– -$6.3M -310,000 Closed
AG
46
Artal Group
Luxembourg
– -$1.02M -50,000 Closed
OAM
47
Oxford Asset Management
United Kingdom
– -$365K -17,954 Closed
LCM
48
Laurion Capital Management
New York
– -$305K -15,000 Closed
PCP
49
Proficio Capital Partners
Massachusetts
– +$373 +17 New
1
2

YMAB Hedge Fund Activity: Q1 2019 in Review

45 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2019, worth a combined $222M — up 27% from $176M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new YMAB positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 14 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $11.4M. The largest seller was Scopia Capital Management, cutting an estimated $14.7M.

  • 45 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2019, up from 42 in Q4 2018.
  • Funds reported $222M of Y-mAbs Therapeutics stock for Q1 2019, up 27% quarter-over-quarter.
  • 7 funds opened new Y-mAbs Therapeutics positions in Q1 2019 and 4 closed out, a net change of +3 holders.
  • The largest Y-mAbs Therapeutics buyer in Q1 2019 was Cormorant Asset Management, an estimated $11.4M added.
  • The largest Y-mAbs Therapeutics seller in Q1 2019 was Scopia Capital Management, an estimated $14.7M sold.

Based on aggregated 13F filings for Q1 2019.